Palestrante
Ludmilla David de Moura
Biomédica (UFU/MG), Mestre em Nanociência e Nanobiotecnologia (UnB, DF) e Doutora em Biologia Funcional e Molecular na área de Bioquímica (Unicamp, SP). Membro da Sociedade Brasileira de Biofísica (SBBF) e associada a “Controlled Release Society (CRS)”. Pesquisadora bolsista no programa “Foundations of Clinical Research” na Harvard Medical School (HMS). Pesquisadora colaboradora do Laboratório de Biomembranas da Unicamp/SP. Formulation Scientist na biofarmacêutica LIBERA BIO S.L. (Espanha), responsável pelo desenvolvimento e caracterização de nanopartículas para o tratamento de cânceres. Atua nas áreas: 1. Nanotecnologia Farmacêutica – desenvolvimento de drug delivery systems (DDS) com princípios Quality-by-Design (QbD) e metodologia Design of Experiments (DoE), embasados nas legislações de registro e pós-registro de medicamentos (FDA/EMA). 2. Biofísica de Sistemas: caracterizações estruturais, analíticas e mecânicas de nanoformulações e escalonamento de produção. 3. Ensaios Clínicos e Pré-Clínicos - cultura de células (2D/3D) e citologia oncótica; modelos in vivo, análises de imageamento e anatomia patológica.
Biomedical (UFU/MG), Master in Nanoscience and Nanobiotechnology (UnB, DF), and Ph.D. in Functional and Molecular Biology in the field of Biochemistry (Unicamp, SP). Member of the Brazilian Society of Biophysics (SBBF) and associate of the Controlled Release Society (CRS). Fellow Researcher in the Foundations of Clinical Research program at Harvard Medical School (HMS). Collaborating Researcher at the Laboratory of Biomembranes at Unicamp/SP. Formulation Scientist at LIBERA BIO S.L. (Spain), responsible for the development and characterization of nanoparticles for the treatment of cancers. Main areas of expertise - 1. Pharmaceutical Nanotechnology – development of drug delivery systems (DDS) with Quality-by-Design (QbD) principles and Design of Experiments (DoE) methodology, based on guidelines and regulations (FDA/ EMA). 2. Biophysics of Systems: structural, analytical, and mechanical characterizations of nanoformulations and production scaling. 3. Clinical and Pre-Clinical Trials - cell culture (2D/3D) and oncotic cytology; in vivo models, imaging analysis, and pathological anatomy.
